Successful emergency transcatheter aortic valve replacement in the setting of hemodynamically unstable prosthetic aortic valve stenosis.
Muhammad IshaqMuhammad Shoaib KhanAmir ShahbazJayanth G VedreAlon YarkoniRhianna MalovrhJuan MesaPublished in: Journal of cardiovascular and thoracic research (2022)
FDA approved transcatheter aortic valve replacement (TAVR) for the treatment of symptomatic aortic valve (AV) stenosis. Recent evidence reveals that TAVR is the treatment of choice in most patients with AV stenosis who are at high risk for surgical aortic valve replacement (SAVR). Per AHA guidelines, repeat valve replacement has been recommended for bio-prosthetic AV stenosis. Urgent TAVR for hemodynamically unstable patients with prosthetic AV stenosis is not supported by significant scientific data. However, there have been a few cases reported on emergency TAVR procedures in hemodynamically unstable patients with severe native AV stenosis. We are reporting a unique case of successful emergency TAVR in a hemodynamically unstable patient, who had severe symptomatic bio-prosthetic AV stenosis at the time of presentation.
Keyphrases
- aortic valve
- transcatheter aortic valve replacement
- aortic valve replacement
- aortic stenosis
- transcatheter aortic valve implantation
- public health
- emergency department
- ejection fraction
- healthcare
- case report
- combination therapy
- coronary artery disease
- clinical practice
- mitral valve
- deep learning
- atrial fibrillation
- artificial intelligence